Delhi government fixes RT-PCR, RAT Covid tests price for private labs

Delhi government on Thursday fixed the price for RTPCR and rapid antigen test for Covid infection at the private labs.
The maximum price for the RT-PCR COVID-19 tests at private laboratories have been fixed between Rs 300 and 500 for RT-PCR samples collected from home, the state health department said in a notification. 


The price for ‘conventional RT PCR Test wherein samples are collected by Govt. teams from the collection sites by Private sector Labs as requisitioned by the Districts Hospitals’ has been capped at 200 inclusive of all taxes. 


The conventional RT PCR Test wherein samples are collected by Private lab teams for Government and processed further at their lab will cost rs 300 per sample, said the order.


For RT-PCR tests wherein individual gives samples at labs for paid testing at their expenses, the price has been fixed at ₹300. The prices for RT-PCR tests where samples are collected through home visits have been fixed at ₹500.


However, the rapid antigen tests (RAT) will be done at ₹100, as per the order.

Medlarge

Recent Posts

70-year-old undergoes Total Knee Replacement using augmented reality technology

A 70-year-old male underwent a transformative Total Knee Replacement (TKR) procedure, utilizing augmented reality (AR)…

2 hours ago

Doctors remove 16.7 kgs tumor from back of 27-year-old international patient

In an extraordinary display of medical expertise and teamwork, Fortis Memorial Research Institute, Gurugram, has…

2 hours ago

CNS Tuberculosis: Experts prioritize early diagnosis, surgery technique and Brain Shunt Management

Tuberculosis remains a major health problem in India, causing approximately 220,000 deaths each year. In…

2 hours ago

Total 14 Patanjali products license cancelled, SC hearing scheduled for Tuesday

The Uttarakhand government has initiated major action against Baba Ramdev in light of misleading advertisements…

3 days ago

Covishield maker AstraZeneca admits Covid vaccine can cause rare side effects

For the first time post Covid period, the Covishield vaccine maker AstraZeneca has admitted that…

3 days ago

Over 50% of patients face delay in discharge due to mediclaim process: Study

A new study from healthcare provider Pristyn Care found that 5 out of 10 patients…

4 days ago